Karuna's schizophrenia drug passes a closely-watched PhIII test, will head to FDA in mid-2023

Kyle LaHucik

Senior Reporter

An investigational pill that combines a former Eli Lilly CNS compound with an overactive bladder drug was better than placebo at reducing a scale of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Karuna's schizophrenia drug passes a closely-watched PhIII test, will head to FDA in mid-2023

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Karuna's schiz­o­phre­nia drug pass­es a close­ly-watched PhI­II test, will head to FDA in mid-2023

Senior Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Karuna's schizophrenia drug passes a closely-watched PhIII test, will head to FDA in mid-2023